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Case	Report
Unexpected	and	Abnormally	Low	HdL	Cholesterol	Levels	on	
Combination	Hypolipidemic	Therapy
R	Unnikrishnan,	R	das,	R	Jaydip,	C	Sudhakaran,	V	Mohan
Abstract	
In	 general,	 Indians	have	 low	HdL	 cholesterol	 levels.	 Fenofibrate,	 a	 drug	widely	 used	 in	 the	 treatment	 of	
hypertriglyceridemia,	usually	also	increases	HdL	cholesterol.	There	have	been	a	few	reports	in	the	literature	of	a	
paradoxical	decrease	in	serum	HdL-cholesterol	in	patients	treated	with	fenofibrate,	either	alone	or	in	combination	
with	a	statin.		We	report	three	cases	of	paradoxical	decrease	in	serum	HdL-	cholesterol	in	type	2	diabetic	patients	
treated	with	a	statin-fenofibrate	combination.		©
InTROdUCTIOn
The	 fibrate	 group	 of	 drugs,	 widely	 used	 to	 treat	 hypertriglyceridemia	usually	also	 increase	 the	cardio	
protective	HdL-	 cholesterol	 levels.	However,	 there	have	
been	a	 few	 reports	describing	a	paradoxical	decrease	 in	
the	serum	HdL-	cholesterol	in	patients	treated	with	fibrates	
alone1-7	or	in	combination	with	statins.8	This	phenomenon	
has	been	 reported	with	bezafibrate,4,6	 ciprofibrate3,5	 and	
more	 recently,	with	 fenofibrate.7	There	are	 also	 reports	
of	 a	 decrease	 in	HdL	 cholesterol	with	 a	 fibratestatin	
combination.8	We	document	here	three	cases	of	paradoxical	
decrease	in	serum	HdL-cholesterol	in	diabetic	patients	on	
a	statin	 /	fibrate	combination.	We	believe	 this	 is	 the	first	
report	from	India	on	this	topic.
CASE	REPORTS
Case No. 1
A	51	year	old	male	presented	to	our	centre	with	type	
2	diabetes	of	11	years’	duration.	His	diabetes	had	been	
stabilized	with	two	divided	doses	of	insulin	along	with	oral	
hypoglycaemic	agents.	He	was	a	non-	smoker	and	was	on	
treatment	for	hypertension.	
Physical	 examination	 revealed	no	 abnormality.	His	
body	mass	 index	was	26.36	kg/m2,	blood	pressure	was	
110/72	mm	Hg	and	his	 renal	 function	was	normal.	He	
had	been	on	 treatment	 for	 hypercholesterolemia	 and	
was	on	Atorvastatin	(10	mg	daily).	On	this	dose,	his	serum	
lipid	values	were:	 serum	cholesterol:	 164	mg/dl;	 serum	
triglycerides:	327	mg/dL;	HdL	cholesterol:	36	mg/dl;	LdL	
cholesterol:	63	mg/dl;	VLdL	cholesterol:	65	mg/dL.	In	view	
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of	the	raised	triglycerides,	he	was	started	on	a	combination	
of	Atorvastatin	 (10	mg	daily)	 and	 fenofibrate	 (200	mg	
daily).		When	he	returned	for	follow-up	after	6	months,	his
lipid	profile	was	as	follows:	serum	cholesterol:	89	mg/dL;	
serum	triglycerides:	123	mg/dl;	LdL	cholesterol:	62	mg/dL;	
VLdL	cholesterol:	25	mg/dL	and	the	HdL	cholesterol	had	
dropped	to	dangerously	low	level	of	2	mg/dL.	Fenofibrate	
was	stopped	and	substituted	with	micronised	niacin	375	
mg	daily.	However	the	patient	could	not	continue	therapy	
with	niacin	 since	he	developed	 severe	 flushing.	Hence	
niacin	therapy	was	stopped	and	therapy	was	continued	with	
atorvastatin	alone.	After	therapy	with	atorvastatin	alone,	his	
HdL	cholesterol	level	rose	again	to	34	mg/dl.	
Case	no.	2	
A	 46	 year	 old	male	 presented	 to	 our	 centre	with	
type	2	dM	associated	with	 systemic	hypertension	and	
dyslipidaemia.	He	was	overweight	and	had	a	blood	pressure	
of	140/90	mm	of	Hg.	He	is	a	non-smoker	and	his	diabetes	
was	under	good	control	with	oral	hypoglycemic	agents.	
His	renal	function	was	normal.	He	had	been	on	treatment	
for	dyslipidaemia	with	fenofibrate	(200	mg).	On	this	dose,	
his	serum	lipid	values	were:	serum	cholesterol:	180	mg/dl;	
serum	triglycerides:	237	mg/dl;	serum	HdL:	21mg/dl;	and	
serum	LdL:	131	mg/dl	 respectively.	 In	view	of	 the	 raised	
triglycerides	and	LdL,	he	was	started	on	a	combination	of	
atorvastatin	and	fenofibrate.	At	the	next	visit	6	months	later,	
his	serum	HdL	cholesterol	was	found	to	have	dropped	to	8	
mg/dl.	The	fenofibrate	was	stopped	and	after	this,	his	HdL	
cholesterol	increased	to	23	mg/dl	with	atorvastatin	alone.
Case No. 3
A	 49	 year	 old	male,	 a	 non-smoker	 and	 teetotaller	
presented	to	our	centre	with	type	2	diabetes	of	10	years’	
duration,	 associated	with	 diabetic	 retinopathy	 and	
neuropathy	and	hyperlipidaemia.	His	diabetes	was	under	
good	control	with	 two	divided	doses	of	 insulin	and	oral	
hypoglycaemic	agents.	His	renal	function	was	normal.
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For	hyperlipidaemia,	he	had	been	on	 treatment with	
atorvastatin	10	mg	daily.	With	 this	dose,	his	 serum	 lipid	
values	were:	 serum	cholesterol:	202	mg/dl;	 triglycerides	
453	mg/dl;	 and	HdL	 cholesterol:	 38	mg/dl.	 In	 view	of	
raised	 triglycerides,	he	was	 started	on	a	combination	of	
atorvastatin	and	fenofibrate.	When	he	came	for	follow	up	
after	a	month,	his	HdL	cholesterol	had	dropped	to	12	mg/
dl	and	triglycerides	to	305	mg/dl.	At	this	time,	fenofibrate	
was	substituted	with	gemfibrozil.	After	3	months,	his	HdL	
cholesterol	rose	to	33	mg/dl	but	triglycerides	remained	high	
at	405	mg/dl.	Atorvastatin	and	 fenofibrate	combination	
was	reintroduced	at	this	time.	At	the	next	follow	up	after	
5	months,	the	serum	HdL	cholesterol	had	again	dropped	
to	6	mg/dl.	After	 stopping	 the	combination,	 serum	HdL	
cholesterol	again	picked	up	to	21	mg/dl	with	gemfibrozil	
alone.	
DISCUSSIOn	
Fibrates, 	 general ly 	 prescr ibed	 for 	 control 	 of	
hypertriglyceridemia,	 usually	 produce	 a	 concomitant	
increase	in	HdL	cholesterol.	A	paradoxical	decrease	in	serum	
HdL	cholesterol	 concentration	has	been	 reported	with	
several	fibrate	compounds.1-7	However,	the	mechanism	of	
this	phenomenon	largely	remains	unclear.	
A	 review	of	 the	 literature	 reveals	 several	 interesting	
aspects	to	this	phenomenon,	namely	(i)	it	occurs	with	fibrate	
monotherapy	and	/	or	statin	+	fibrate	combination	therapy	
(ii)	it	appears	to	be	a	class	effect	of	the	fibric	acid	derivatives	
(iii)	there	may	sometimes	be	a	fibrate	dose	dependency	(iv)	
it	may	not	be	consistently	 reproducible,	 if	 such	patients	
are	 re-challenged	with	fibrate	 (v)	 there	 is	 an	 increased	
catabolism	and	decreased	synthesis	of	apolipoprotein	A	
containing	lipoprotein	(vi)	it	may	become	evident	as	early	
as	 two	weeks	after	 initiation	of	fibrate	 therapy	and	 full	
recovery	may	be	observed	within	two	weeks	after	cessation	
of	the	fibrate.2
There	is	only	one	report	in	the	literature	of	a	paradoxical	
decline	 in	 serum	HdL	cholesterol	 induced	by	a	 statin	 /	
fibrate	combination8	but	in	that	case	it	was	associated	with	
abnormal	renal	function	which	could	have	contributed	to	
this	phenomenon.	To	our	knowledge,	our	cases	are	unique	in	
being	the	first	report	of	a	paradoxical	and	profound	decrease	
in	HdL	cholesterol	levels	with	a	statin	/	fibrate	combination	
in	diabetic	patients	without	renal	impairment.	In	all	three	
cases	 reported	here,	 the	statin	was	atorvastatin	and	 the	
fibrate	was	 fenofibrate.	This	 suggests	 that	 this	particular	
combination	may	be	more	prone	 to	produce	unusually	
low	HdL	cholesterol	 levels.	However	we	cannot	 rule	out	
the	possibility	that	other	statin	/	fibrate	combinations	may	
also	make	patients	more	prone	to	this	phenomenon.	The	
message	to	practising	physicians	is	that	whenever	a	statin/	
fibrate	combination	is	used,	in	addition	to	looking	for	risk	
of	myopathies,	one	should	also	look	out	for	precipitous	fall	
in	HdL	cholesterol	levels.	This	is	particularly	relevant	in	the	
context	of	Asian	 Indians	who	are	already	known	to	have	
low	HdL	cholesterol	levels.9
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